Landing

Mission Control for Next-Generation Genetic Delivery

Atlas Architect is a strategic decision layer for translational teams designing in-vivo delivery architectures. It centers where first-generation AAV fails and what engineering choices improve efficacy, specificity, safety, manufacturability, and translation.

Clinically real modality, strategic redesign

From first-generation AAV limits to decision-grade next-step design.

AAV is validated in clinic, but many programs still fail on dose, specificity, immunity, barrier access, and translation. Atlas Architect helps teams decide what to build next—and what to test before committing.

Top recommendation preview

Engineered AAV systemic CNS delivery

Strong therapeutic fit for broad CNS coverage with durable expression, contingent on liver detargeting and antibody escape improvements.

Confidence

Next: NHP biodistribution + anti-capsid seroprevalence stratified transduction study.

Current bottlenecks in first-generation AAV

Low target-organ transduction efficiency at clinically tolerable doses

Liver sink and off-target burden in systemic exposure

Insufficient barrier penetration (BBB, retinal layers, cochlear compartments)

Pre-existing neutralizing antibodies and de novo immune activation

Manufacturability constraints and species translation uncertainty

Post-entry trafficking and nuclear fate inefficiency